Trevi Therapeutics, Inc. (TRVI) – What Are Analysts Thinking About This Stock?

Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) have been assigned a consensus rating of “Moderate Buy” from the thirteen analysts that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $27.08.

Several research firms have issued reports on TRVI. Wall Street Zen downgraded shares of Trevi Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, July 25th. Raymond James Financial reissued a “strong-buy” rating and set a $40.00 target price on shares of Trevi Therapeutics in a research note on Friday, August 7th. Oppenheimer reaffirmed an “outperform” rating on shares of Trevi Therapeutics in a research note on Friday, September 25th. B. Riley Financial raised their target price on shares of Trevi Therapeutics from $21.00 to $31.00 and gave the stock a “buy” rating in a report on Monday, July 20th. Finally, Cantor Fitzgerald increased their price target on shares of Trevi Therapeutics from $25.00 to $30.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th.

Trevi Therapeutics Trading Up 0.2%

TRVI traded up $0.03 during midday trading on Friday, hitting $13.65. The company’s stock had a trading volume of 1,099,901 shares, compared to its average volume of 1,702,979. Trevi Therapeutics has a 52-week low of $9.82 and a 52-week high of $20.22. The firm has a 50-day moving average price of $14.03 and a two-hundred day moving average price of $14.49. The firm has a market cap of $1.95 billion, a P/E ratio of -35.00 and a beta of 1.15.

Trevi Therapeutics (NASDAQ:TRVI) last released its earnings results on Monday, November 9th. The company reported ($0.13) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.13). On average, equities analysts expect that Trevi Therapeutics will post -0.49 EPS for the current year.

Insider Buying and Selling

In other Trevi Therapeutics news, Director Michael Heffernan sold 39,473 shares of the business’s stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $15.09, for a total transaction of $595,647.57. Following the completion of the transaction, the director owned 6,351 shares of the company’s stock, valued at $95,836.59. The trade was a 86.14% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 15.39% of the stock is owned by company insiders.

Institutional Trading of Trevi Therapeutics

Hedge funds have recently modified their holdings of the company. KBC Group NV acquired a new stake in Trevi Therapeutics during the first quarter valued at approximately $29,000. Sterling Capital Management LLC lifted its stake in shares of Trevi Therapeutics by 848.7% in the 3rd quarter. Sterling Capital Management LLC now owns 3,567 shares of the company’s stock valued at $51,000 after purchasing an additional 3,191 shares during the period. Avidity Partners Management LP acquired a new stake in shares of Trevi Therapeutics in the 1st quarter valued at approximately $79,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in Trevi Therapeutics in the third quarter valued at about $104,000. Finally, Amundi bought a new position in Trevi Therapeutics in the second quarter valued at approximately $192,000. Institutional investors own 95.76% of the company’s stock.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for chronic cough and chronic itch. Its lead candidate, Haduvio (oral extended-release nalbuphine), is being studied for conditions including idiopathic pulmonary fibrosis, other interstitial lung diseases and chronic pruritus associated with prurigo nodularis. Nalbuphine acts on opioid receptors, and Trevi is evaluating its potential to reduce these symptoms. The company’s development programs are focused on clinical research; Haduvio is not an approved treatment.